XBIT — XBiotech Inc.
$1.93-2.03%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for XBIT in the TickerWise workspace.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 92
- Website: https://www.xbiotech.com
Latest SEC filings for XBIT
Latest XBIT news
- XBiotech gibt die Wahl von Sushma Shivaswamy und Jan-Paul Simard zu Co-Chief Executive Officers bekannt Read article
- XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux Read article
- XBiotech gibt positive endgültige Wirksamkeitsergebnisse der Phase-II-Studie „TASKIN“ bekannt, einer von Forschern initiierten Studie zur Behandlung von refraktärem metastasiertem Kolorektalkarzinom Read article
- XBiotech annonce des résultats d’efficacité finaux positifs de phase II pour l’essai TASKIN commandité par un chercheur dans le cancer colorectal métastatique réfractaire Read article
- XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.